Penetration of temafloxacin into body tissues and fluids.

The new fluoroquinolone antimicrobial temafloxacin shows good penetration into a range of body tissues and fluids, after single or repeated oral administration to healthy volunteers and patients undergoing various procedures. Temafloxacin concentrations in respiratory tissues and fluids, nasal secretions, tonsils, prostate, semen, bone and blister fluid were similar to, or greater than, concurrent serum concentrations. Penetration into sinus secretions and cerebrospinal fluid is less marked; nevertheless, temafloxacin concentrations of approximately 2.

Hepatobiliary elimination of temafloxacin.

The biliary excretion of temafloxacin and temafloxacin glucuronide was characterised in this study after administration of a single oral temafloxacin 600mg dose to 8 patients with T-tube drainage of the common bile duct inserted after cholecystectomy or choledochotomy. High performance liquid chromatographic analyses of plasma, urine and bile samples collected during the 72h after temafloxacin administration showed that biliary concentrations of unchanged temafloxacin followed a time-course parallel to plasma concentrations but were 5- to 10-fold higher. Biliary temafloxacin peak concentrations ranged from 18.

Pharmacokinetics of temafloxacin in patients with liver impairment.

A multicentre study was conducted to determine whether liver impairment would alter the pharmacokinetics of temafloxacin, a new fluoroquinolone antimicrobial agent. 16 patients with cirrhosis and 12 healthy volunteers (the control group) received a single oral 600mg dose of temafloxacin. Blood and urine were sampled at frequent intervals after drug administration and assayed by high performance liquid chromatography.

Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.

Temafloxacin is a new antibacterial agent of the fluoroquinolone group. In comparison with ciprofloxacin, the current leading quinolone, temafloxacin shows higher and longer lasting plasma concentrations after equivalent doses due to an almost complete gastrointestinal absorption and a lower total clearance. Temafloxacin absorption is little influenced by food intake.

Determination of oxprenolol and its glucuronide metabolite in plasma and urine using high-performance liquid chromatography.

A HPLC assay is presented for the determination of oxprenolol (1) and its glucuronic acid conjugate (2) in human plasma and urine. The procedure employs a selective re-extraction using alprenolol (3) as the internal standard, followed by reversed-phase chromatography and UV-detection. The minimal detectable concentration is 10 ng/ml in plasma and 50 ng/ml in urine, using 1.

Pharmacokinetic disposition of quinolones in human body fluids and tissues.

The unique pharmacokinetic properties as well as the body fluid and tissue penetration of quinolones are discussed. Quinolones are well absorbed from the gastrointestinal tract and are eliminated with considerable differences in their terminal half-lives. The major elimination pathways of quinolones are renal excretion and hepatic metabolism.